Status:
TERMINATED
Common Safety Follow-up Trial of Tecemotide (L-BLP25)
Lead Sponsor:
Merck KGaA, Darmstadt, Germany
Conditions:
Non-Small Cell Lung Cancer
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is an open-label, common follow-up trial. Subjects who were enrolled in a Merck KGaA, EMD Serono or Merck Serono Japan sponsored trial with tecemotide (L-BLP25) were enrolled in this follow-up tr...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Signed written informed consent.
- Registration and treatment in a clinical trial with tecemotide (L-BLP25) under sponsorship of Merck KGaA/EMD Serono/Merck Serono Japan (feeder trial). \[Note, subjects who have been allocated to treatments not containing tecemotide (L BLP25) in the feeder trial are eligible for this trial and will be followed-up for progressive disease (PD) (if applicable) and survival.\]
- End of Treatment procedures have been performed in the feeder trial.
- Other protocol defined inclusion criteria could apply
- Exclusion Criteria
- Pregnancy and lactation period; women of childbearing potential, unless using effective contraception as determined by the Investigator. Subjects whom the Investigator considers may be at risk of pregnancy will have a pregnancy test performed per institutional standard
- Known hypersensitivity to any of the trial treatment ingredients (if applicable)
- Legal incapacity or limited legal capacity
- Any other reason that, in the opinion of the Investigator, precludes the subject from participating in the trial
- Other protocol defined exclusion criteria could apply
Exclusion
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2015
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT01423760
Start Date
January 1 2012
End Date
August 1 2015
Last Update
October 6 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Merck KGaA Communication Center
Darmstadt, Germany